First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]

Cyclo-oxygenase-2 selective inhibitors are frequently used to manage osteoarthritis. We compared the analgesic efficacy of the novel cyclo-oxygenase-2 selective inhibitor lumiracoxib (Prexige(®)) versus placebo and celecoxib in patients with knee osteoarthritis. This seven day, double-blind, placebo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Wittenberg, Ralf H, Schell, Ernest, Krehan, Gerhard, Maeumbaed, Roland, Runge, Hans, Schlüter, Peter, Fashola, Taiwo OA, Thurston, Helen J, Burger, Klaus J, Trechsel, Ulrich
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2006
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1526611/
https://ncbi.nlm.nih.gov/pubmed/16469112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar1854
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller